Emergence of the CD226 Axis in Cancer Immunotherapy

被引：25

作者：

Conner, Michael ^{[1
]}

Hance, Ken W. ^{[1
]}

Yadavilli, Sapna ^{[1
]}

Smothers, James ^{[1
]}

Waight, Jeremy D. ^{[1
]}

机构：

[1] GlaxoSmithKline, Oncol R&D, Collegeville, PA 19426 USA

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

关键词：

cancer immunotherapy; NK cells; T cells; Treg cells; antibodies; fc gamma receptors (Fc gamma R); NATURAL-KILLER-CELLS; DNA-DAMAGE RESPONSE; CHECKPOINT RECEPTOR TIGIT; MULTIPLE-MYELOMA CELLS; REGULATORY T-CELLS; LIGAND EXPRESSION; CD155; EXPRESSION; DENDRITIC CELLS; NECTIN-2; CD112; NKG2D LIGANDS;

D O I：

10.3389/fimmu.2022.914406

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In recent years, a set of immune receptors that interact with members of the nectin/nectin-like (necl) family has garnered significant attention as possible points of manipulation in cancer. Central to this axis, CD226, TIGIT, and CD96 represent ligand (CD155)-competitive co-stimulatory/inhibitory receptors, analogous to the CTLA-4/B7/CD28 tripartite. The identification of PVRIG (CD112R) and CD112 has introduced complexity and enabled additional nodes of therapeutic intervention. By virtue of the clinical progression of TIGIT antagonists and emergence of novel CD96- and PVRIG-based approaches, our overall understanding of the 'CD226 axis' in cancer immunotherapy is starting to take shape. However, several questions remain regarding the unique characteristics of, and mechanistic interplay between, each receptor-ligand pair. This review provides an overview of the CD226 axis in the context of cancer, with a focus on the status of immunotherapeutic strategies (TIGIT, CD96, and PVRIG) and their underlying biology (i.e., cis/trans interactions). We also integrate our emerging knowledge of the immune populations involved, key considerations for Fc gamma (gamma) receptor biology in therapeutic activity, and a snapshot of the rapidly evolving clinical landscape.

引用

页数：19

共 172 条

[1] CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity [J].

Aguilera, Amelia Roman ;

Lutzky, Viviana P. ;

Mittal, Deepak ;

Li, Xian-Yang ;

Stannard, Kimberley ;

Takeda, Kazuyoshi ;

Bernhardt, Guenter ;

Teng, Michele W. L. ;

Dougall, William C. ;

Smyth, Mark J. .

ONCOIMMUNOLOGY, 2018, 7 (05)

[2] Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups [J].

Andrews, Lawrence P. ;

Yano, Hiroshi ;

Vignali, Dario A. A. .

NATURE IMMUNOLOGY, 2019, 20 (11) :1425-1434

[3] Expression of DNAM-1 (CD226) on inflammatory monocytes [J].

Anh Van Vo ;

Takenaka, Eri ;

Shibuya, Akira ;

Shibuya, Kazuko .

MOLECULAR IMMUNOLOGY, 2016, 69 :70-76

[4] DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction [J].

Ardolino, Michele ;

Zingoni, Alessandra ;

Cerboni, Cristina ;

Cecere, Francesca ;

Soriani, Alessandra ;

Iannitto, Maria Luisa ;

Santoni, Angela .

BLOOD, 2011, 117 (18) :4778-4786

[5] Anti-TIGIT biomarker study: Inhibition of TIGIT induces loss of Tregs from tumors and requires effector function for tumor growth inhibition [J].

Argast, Gretchen M. ;

Cancilla, Belinda ;

Cattaruzza, Fiore ;

Yeung, Pete ;

le Scolan, Erwan ;

Harris, Rose ;

Lahmy, Reyhaneh ;

Brunner, Alayne ;

Wang, Min ;

O'Young, Gilbert ;

Lowe, Earth Light ;

Axelrod, Fumiko ;

Monteon, Jorge ;

Elechko, Jennifer ;

Lam, Andrew ;

Xie, MingHong ;

Gurney, Austin ;

Lewicki, John ;

Kapoun, Ann .

CANCER RESEARCH, 2018, 78 (13)

[6] Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses [J].

Banta, Karl L. ;

Xu, Xiaozheng ;

Chitre, Avantika S. ;

Au-Yeung, Amelia ;

Takahashi, Chikara ;

O'Gorman, William E. ;

Wu, Thomas D. ;

Mittman, Stephanie ;

Cubas, Rafael ;

Comps-Agrar, Laetitia ;

Fulzele, Amit ;

Bennett, Eric J. ;

Grogan, Jane L. ;

Hui, Enfu ;

Chiang, Eugene Y. ;

Mellman, Ira .

IMMUNITY, 2022, 55 (03) :512-+

[7] Identification of secreted CD155 isoforms [J].

Baury, W ;

Masson, D ;

McDermott, BM ;

Jarry, A ;

Blottière, HM ;

Blanchardie, P ;

Laboisse, CL ;

Lustenberger, P ;

Racaniello, VR ;

Denis, MG .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 309 (01) :175-182

[8] Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms [J].

Beltra, Jean-Christophe ;

Manne, Sasikanth ;

Abdel-Hakeem, Mohamed S. ;

Kurachi, Makoto ;

Giles, Josephine R. ;

Chen, Zeyu ;

Casella, Valentina ;

Ngiow, Shin Foong ;

Khan, Omar ;

Huang, Yinghui Jane ;

Yan, Patrick ;

Nzingha, Kito ;

Xu, Wei ;

Amaravadi, Ravi K. ;

Xu, Xiaowei ;

Karakousis, Giorgos C. ;

Mitchell, Tara C. ;

Schuchter, Lynn M. ;

Huang, Alexander C. ;

Wherry, E. John .

IMMUNITY, 2020, 52 (05) :825-+

[9] Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells [J].

Bengsch, Bertram ;

Ohtani, Takuya ;

Khan, Omar ;

Setty, Manu ;

Manne, Sasikanth ;

O'Brien, Shaun ;

Gherardini, Pier Federico ;

Herati, Ramin Sedaghat ;

Huang, Alexander C. ;

Chang, Kyong-Mi ;

Newell, Evan W. ;

Bovenschen, Niels ;

Pe'er, Dana ;

Albelda, Steven M. ;

Wherry, E. John .

IMMUNITY, 2018, 48 (05) :1029-+

[10]

Bevelacqua V, 2012, ONCOTARGET, V3, P879

← 1 2 3 4 5 6 7 8 9 10 →